Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALEVE vs DIMETANE-DX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
Dimetane-DX contains brompheniramine (first-generation antihistamine) and dextromethorphan (NMDA receptor antagonist and sigma-1 agonist). Brompheniramine antagonizes histamine at H1 receptors, reducing allergic symptoms; dextromethorphan suppresses cough by acting on the cough center in the medulla oblongata via NMDA receptor antagonism and sigma-1 receptor activation.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Juvenile arthritis,Tendonitis,Bursitis,Acute gout,Primary dysmenorrhea,Mild to moderate pain,Fever
Relief of cough and upper respiratory symptoms associated with allergy or common cold (FDA-approved OTC use)
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
Adults and children ≥12 years: One tablet (brompheniramine 4 mg, dextromethorphan 10 mg, phenylephrine 10 mg) orally every 4 hours as needed, not to exceed 4 doses in 24 hours.
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
Brompheniramine: 25-30 hours; guaifenesin: 1 hour; dextromethorphan: 2-4 hours (CYP2D6 extensive metabolizers) or 20-40 hours (poor metabolizers).
Naproxen is extensively metabolized in the liver primarily via CYP2C9 to 6-O-desmethyl naproxen, and less than 5% is excreted unchanged in urine.
Brompheniramine is hepatically metabolized via CYP450 enzymes (primarily CYP2D6). Dextromethorphan is extensively metabolized by CYP2D6 to dextrorphan (active metabolite).
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
Renal: 50-70% (brompheniramine) as metabolites and unchanged drug; guaifenesin metabolites primarily renal; dextromethorphan and metabolites renal. Biliary/fecal: minor.
>99% bound to albumin; saturable at high concentrations.
Brompheniramine: 50-60% to albumin; guaifenesin: <5%; dextromethorphan: 60-70% to albumin.
0.16 L/kg; indicates distribution primarily in extracellular fluid.
Brompheniramine: 1.5-2.0 L/kg; guaifenesin: 0.5-1.0 L/kg; dextromethorphan: 5-10 L/kg.
Oral: ~95%; immediate-release formulation.
Oral: brompheniramine 50-70%, guaifenesin 70-90%, dextromethorphan 40-60% (first-pass metabolism).
GFR 30-59 m L/min: reduce dose and avoid long-term use; GFR <30 m L/min: contraindicated.
e GFR 30–59 m L/min: Administer with caution and reduce frequency to every 6 hours. e GFR <30 m L/min: Avoid use due to risk of accumulation of dextromethorphan and phenylephrine.
Child-Pugh class A: no adjustment; Child-Pugh class B or C: avoid use.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dosing interval to every 8 hours; use with caution. Child-Pugh Class C: Contraindicated due to extensive first-pass metabolism.
2-12 years: 2.5-5 mg/kg/dose orally every 8-12 hours; maximum 10 mg/kg/day. 12 years and older: same as adult.
Children 6–11 years: 5 m L (half the adult dose) of liquid formulation (brompheniramine 2 mg, dextromethorphan 5 mg, phenylephrine 5 mg per 5 m L) orally every 4 hours, max 4 doses/day. Children 2–5 years: 2.5 m L orally every 4 hours, max 4 doses/day. Children <2 years: Contraindicated.
Initiate at lowest effective dose (220 mg every 12 hours); maximum 440 mg per day; monitor renal function and GI bleeding risk.
Age ≥65 years: Initiate at half the adult dose (e.g., one tablet every 8 hours) due to increased anticholinergic effects and risk of urinary retention, constipation, and dizziness. Avoid in frail elderly or those with cognitive impairment.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. Naproxen is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease or GI bleeding are at greater risk.
None.
Cardiovascular thrombotic events,Gastrointestinal bleeding, ulceration, and perforation,Hypertension,Heart failure and edema,Renal toxicity,Anaphylactoid reactions,Serious skin reactions (e.g., Stevens-Johnson syndrome),Hematologic toxicity (inhibition of platelet aggregation),Exacerbation of asthma,Hepatic effects,Pregnancy: avoid during third trimester
Do not use with MAOIs or for 2 weeks after stopping MAOIs due to risk of serotonin syndrome (dextromethorphan).,Avoid use in patients with asthma, chronic bronchitis, emphysema, or persistent cough (may suppress cough reflex).,Use with caution in patients with glaucoma, prostatic hyperplasia, urinary retention, or hypertension (brompheniramine anticholinergic effects).,CNS depression risk: may cause drowsiness; avoid alcohol or other sedatives.
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Peri-operative pain in the setting of CABG surgery,Advanced renal disease,History of gastrointestinal bleeding or perforation related to previous NSAID therapy,Active gastrointestinal bleed
Concurrent MAOI therapy or within 14 days,Neonates or premature infants (brompheniramine),Breastfeeding (may suppress lactation; dextromethorphan safety not established),Severe hypertension or coronary artery disease (brompheniramine may increase heart rate)
Avoid concurrent use of alcohol as it increases GI bleeding risk. No specific food restrictions; taking with food or milk may reduce dyspepsia. High potassium foods (e.g., bananas, spinach) may increase hyperkalemia risk in patients with renal impairment.
Avoid concurrent use of tyramine-rich foods (e.g., aged cheeses, cured meats, soy sauce, fermented foods) due to risk of hypertensive crisis with sympathomimetic (phenylephrine). Grapefruit juice may increase dextromethorphan levels; avoid large amounts.
First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arteriosus premature closure risk begins. Third trimester: High risk of premature closure of ductus arteriosus, oligohydramnios, necrotizing enterocolitis, intracranial hemorrhage, and renal impairment; avoid after 30 weeks.
Dimetane-DX contains brompheniramine (antihistamine) and dextromethorphan (antitussive). First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Avoid due to risk of neonatal respiratory depression, withdrawal symptoms, and anticholinergic effects. Dextromethorphan: No clear teratogenic risk, but avoid use. Overall: Contraindicated in pregnancy unless benefit outweighs risk.
Excreted in breast milk in low concentrations (M/P ratio ~0.12); relative infant dose <1% of maternal weight-adjusted dose. Compatible with breastfeeding; monitor infant for potential adverse effects (gastrointestinal upset, rash) at higher doses.
Brompheniramine may suppress lactation and cause irritability in infants. Dextromethorphan is excreted in breast milk in small amounts (M/P ratio not well defined). Use with caution; consider alternative therapy.
No specific pharmacokinetic-based dose adjustments; however, use lowest effective dose for shortest duration, especially after 20 weeks. Avoid use after 30 weeks gestation due to fetal risks. Increased volume of distribution may reduce serum concentrations but no dose adjustment recommended.
No specific dose adjustments are recommended for Dimetane-DX in pregnancy due to limited data. However, increased plasma volume and altered drug metabolism may reduce efficacy; clinicians should consider lowest effective dose and shortest duration. Avoid near delivery.
ALEVE (naproxen sodium) is a nonsteroidal anti-inflammatory drug (NSAID) with a longer half-life (12-17 hours) allowing twice-daily dosing. It carries a boxed warning for cardiovascular and gastrointestinal risk. Use lowest effective dose for shortest duration. Contraindicated in patients with aspirin allergy, perioperative pain in CABG surgery, and significant renal impairment. Monitor renal function in elderly, volume-depleted patients, and those on ACE inhibitors or diuretics.
DIMETANE-DX combines brompheniramine (first-generation antihistamine), phenylephrine (decongestant), and dextromethorphan (antitussive). Avoid in hypertension, MAOI use, or asthma. Monitor for CNS depression and anticholinergic effects.
Take with food or milk to reduce GI upset.,Do not exceed 2 tablets (440 mg) in 24 hours unless directed by a doctor.,Avoid alcohol consumption to lower risk of GI bleeding.,Stop use and seek medical help if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (black/tarry stools, vomit that looks like coffee grounds).,Do not use with other NSAIDs (e.g., ibuprofen, aspirin) unless prescribed.
Do not drive or operate machinery until you know how this medication affects you; it may cause drowsiness or dizziness.,Avoid alcohol and other sedatives; they increase sedation and CNS depression.,Do not exceed recommended dosage or use for more than 7 days for cough.,Stop use and consult a doctor if symptoms persist or worsen, or if you develop fever, rash, or persistent headache.,Inform your healthcare provider if you have high blood pressure, heart disease, glaucoma, or urinary retention.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALEVE vs DIMETANE-DX, answered by our medical review team.
ALEVE is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.. DIMETANE-DX is a Antitussive Combination that works by Dimetane-DX contains brompheniramine (first-generation antihistamine) and dextromethorphan (NMDA receptor antagonist and sigma-1 agonist). Brompheniramine antagonizes histamine at H1 receptors, reducing allergic symptoms; dextromethorphan suppresses cough by acting on the cough center in the medulla oblongata via NMDA receptor antagonism and sigma-1 receptor activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALEVE and DIMETANE-DX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALEVE is: 220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.. The standard adult dose of DIMETANE-DX is: Adults and children ≥12 years: One tablet (brompheniramine 4 mg, dextromethorphan 10 mg, phenylephrine 10 mg) orally every 4 hours as needed, not to exceed 4 doses in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALEVE and DIMETANE-DX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALEVE is classified as Category C. First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arter. DIMETANE-DX is classified as Category C. Dimetane-DX contains brompheniramine (antihistamine) and dextromethorphan (antitussive). First trimester: Limited human data; animal studies show no teratogenicity at therapeutic d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.